Status:
COMPLETED
Efficacy Assessment of Lenvatinib Associated with Pembrolizumab in Metastatic Endometrial Cancer: a French Multicentric Retrospective Early Access Program-based Study
Lead Sponsor:
ARCAGY/ GINECO GROUP
Collaborating Sponsors:
Institut Curie
Conditions:
Metastatic Endometrial Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
LARENA is a multicentric retrospective study (secondary use of data) of consecutive patients prospectively registered in the lenvatinib plus pembrolizumab French early access program (Temporary Author...
Eligibility Criteria
Inclusion
- Patients having received at least one dose of lenvatinib plus pembrolizumab in the context of the French early access program (Temporary Authorisation for Use) approved by the French Health Autority.
- Patients with advanced or recurrent endometrial cancer whose disease is progressing during or following prior platinum-based chemotherapy at any stage and who are not eligible for curative surgery or radiotherapy, according to the French early access program (Temporary Authorisation for Use) approved by the French Health Autority criteria.
Exclusion
- Patients who refuse the collection and use of their personal data in the course of this research.
Key Trial Info
Start Date :
August 19 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 28 2025
Estimated Enrollment :
351 Patients enrolled
Trial Details
Trial ID
NCT06599463
Start Date
August 19 2024
End Date
February 28 2025
Last Update
March 20 2025
Active Locations (24)
Enter a location and click search to find clinical trials sorted by distance.
1
ICO Paul Papin
Angers, France, 49055
2
Sainte Catherine - Institut du Cancer Avignon
Avignon, France, 84918
3
CHU Jean Minjoz
Besançon, France, 25000
4
ICONE
Bezannes, France, 51430